Abbisko Cayman Ltd. announced that its subsidiary, Abbisko Therapeutics, presented longer-term efficacy and safety outcomes from the global Phase III MANEUVER study of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumour (TGCT) at the 2025 Connective Tissue Oncology Society $(CTOS)$ Annual Meeting. The analysis indicated that sustained treatment with pimicotinib led to continued improvements in tumor response and patient-reported outcomes including pain and function, while maintaining an acceptable safety profile. The company noted that while these results reinforce the potential for long-term use in eligible patients, there is no guarantee that ABSK021 will ultimately be successfully marketed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.